Klein Peter S
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
RBC raises F5 price target to $525 amid software sector pullback. RBC Capital raised its price target for F5 to $525 while maintaining an Outperform rating. This action occurred as software stocks faced broader pressure from Middle East tensions and inflation concerns. The stock is currently trading near its 52-week high, with an average analyst target of $437.80.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
PDYN Q2 2026 Earnings Call Transcript Released. Palladyne AI Corp. released the transcript of its Q2 2026 earnings call. Management discussed the quarter’s results and provided updates on revenue trends and future outlook. The discussion adds context for investors reviewing the company’s performance amid its current price near the lower end of its 52‑week range.
Transaction History
| DNLI | ▲ Buy | Grant | 6,408 | $0 | 6/3/2026 | View on chart |
| DNLI | ▲ Buy | Grant | 6,037 | $0 | 6/3/2025 | View on chart |
| FFIV | ▲ Buy | Option Exercise | 1,309 | $0 | 3/12/2025 | View on chart |
| FFIV | ▼ Sell | Gift | 1,000 | $0 | 9/5/2024 | View on chart |
| DNLI | ▲ Buy | Grant | 5,967 | $0 | 5/31/2024 | View on chart |
| FFIV | ▲ Buy | Option Exercise | 1,770 | $0 | 3/13/2024 | View on chart |
| FFIV | ▼ Sell | Gift | 1,200 | $0 | 9/5/2023 | View on chart |
| PDYN | ▲ Buy | Grant | 195,059 | $0 | 6/14/2023 | View on chart |
| DNLI | ▲ Buy | Grant | 4,216 | $0 | 6/1/2023 | View on chart |
| FFIV | ▲ Buy | Option Exercise | 1,272 | $0 | 3/8/2023 | View on chart |
| PDYN | ▲ Buy | Grant | 57,692 | $0 | 6/29/2022 | View on chart |
| DNLI | ▲ Buy | Grant | 5,986 | $0 | 6/2/2022 | View on chart |
| FFIV | ▲ Buy | Option Exercise | 1,282 | $0 | 3/9/2022 | View on chart |
| PDYN | ▲ Buy | Grant | 12,315 | $0 | 12/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Denali Therapeutics Shares Test Fair Value Amid Pullback
Denali Therapeutics shares have pulled back, testing the $19.37 support level. The 14‑day RSI sits at 30, indicating a possible oversold condition, while the support_reject signal suggests the level may hold. Analysts average a target of $36.06, with a range of $27 to $42, well above the current price and the 52‑week low of $13.75. The pullback could be seen as a chance to assess fair value.
Denali Therapeutics Shares Test Fair Value Amid Pullback. Denali Therapeutics shares have pulled back, testing the $19.37 support level. The 14‑day RSI sits at 30, indicating a possible oversold condition, while the support_reject signal suggests the level may hold. Analysts average a target of $36.06, with a range of $27 to $42, well above the current price and the 52‑week low of $13.75. The pullback could be seen as a chance to assess fair value.